Is it Possible to Treat Osteosarcoma Using Oligonucleotides Confined into Controlled Release Drug Delivery Systems?

Curr Pharm Biotechnol. 2017;18(6):516-522. doi: 10.2174/1389201018666170615083455.


Purpose: The present study aimed to analyze the researches that are at the experimental phase concerning osteosarcoma treatment. The researches included drug delivery systems which allow controlled release and imbue small interfering-/micro- ribonucleic acid.

Methods: Without any language preference, we searched US National Library of Medicine National Institutes of Health, Embase, OVID, Cochrane Library database of clinical trials from 1843 to May 25, 2016 and traced all the references of incorporated documents. The data were evaluated using descriptive statistics and the results are shown as frequency (%).

Results: We haven't encountered any drug delivery system in which Small interfering ribonucleic acid/ micro ribonucleic acid oligonucleotides were embedded successfully against osteosarcoma. There has been only one research in which hairpin-ribonucleic acid was embedded.

Conclusion: It was considered that drug delivery system enabling controlled oligonucleotide release in the treatment period of osteosarcoma was not projected for the clinical use. However, it cannot be neglected that the mentioned experimental studies with regard to osteosarcoma treatment establish the basis of target therapies. The method in question looks promising regarding effective treatment of osteosarcoma in the future.

Keywords: Controlled release; drug delivery systems; miRNA; osteosarcoma; pharmacogenomics; siRNA.

Publication types

  • Review

MeSH terms

  • Animals
  • Bone Neoplasms / genetics
  • Bone Neoplasms / metabolism
  • Bone Neoplasms / therapy*
  • Delayed-Action Preparations
  • Drug Delivery Systems / methods*
  • Gene Silencing
  • Gene Transfer Techniques*
  • Humans
  • MicroRNAs / administration & dosage*
  • MicroRNAs / genetics
  • Molecular Targeted Therapy
  • Osteosarcoma / genetics
  • Osteosarcoma / metabolism
  • Osteosarcoma / therapy*
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / genetics


  • Delayed-Action Preparations
  • MicroRNAs
  • RNA, Small Interfering